Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, First Once-Daily Treatment for Heavy Menstrual Bleeding Associated
In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL...
David Marek Nick Lagunowich Ayman Al Hendy Program Steering Committee Member Pfizer Inc Myovant Sciences Inc
Source: miragenews.com